Bayesian meta‐analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high‐dose gantenerumab in prodromal and mild Alzheimer's disease

Bayesian meta‐analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high‐dose gantenerumab in prodromal and mild Alzheimer's disease

Abstract INTRODUCTION Phase 3 trials using the anti‐amyloid antibodies aducanumab, lecanemab, donanemab, and high‐dose gantenerumab in prodromal and mild Alzheimer's disease dementia were heterogeneous in respect to statistical significance of effects. However, heterogeneity of results has not...

Full description

Bibliographic Details
Main Authors: Stefan J. Teipel, Anna G. M. Temp, Michael W. Lutz
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
amyloid lowering treatment
Bayes factor
effect size estimate
heterogeneity
prodromal Alzheimer's disease
treatment effect
Online Access:https://doi.org/10.1002/trc2.12454

Internet

https://doi.org/10.1002/trc2.12454

Similar Items